Spinal cord stimulation may improve hip mobility, walking in SMA

Small study suggests technique has potential to 'reshape landscape of care'

Written by Andrea Lobo |

A doctor in scrubs and a mask shows an MRI to a patient in a gown.

Spinal cord stimulation may improve mobility for SMA patients. (Photo by iStock)

Epidural spinal cord stimulation (SCS) may improve walking in people with spinal muscular atrophy (SMA) through better hip mobility and movement without worsening compensatory gait patterns, a small study suggests.

The findings build on previous research showing the procedure improved walking distance, muscle strength, and endurance in adults with SMA, suggesting the approach may help address movement abnormalities that persist despite disease-modifying treatments.

“SCS may be a critical adjuvant intervention with the potential to restore function and reshape the landscape of care in SMA,” the researchers wrote.

The study, “Epidural Spinal Cord Stimulation Reduces Intrinsic Gait Abnormalities in Spinal Muscular Atrophy,” published in Muscle & Nerve, analyzed walking data from two adults with SMA who participated in an earlier clinical trial.

Recommended Reading
after diagnosis

Ella Shares Her Hopes of Walking in the Future

Disease affects mobility

SMA is caused by genetic mutations that lead to the progressive loss of motor neurons — nerve cells that control movement — ultimately resulting in SMA symptoms like muscle weakness and wasting.

Although disease-modifying treatments have improved outcomes and enabled more people with SMA to walk, many patients continue to experience mobility difficulties, including reduced walking speed, fatigue, and compensatory movement patterns.

Spinal cord stimulation involves implanting electrodes into the epidural space (the space between the bone and the spinal cord) to deliver electrical stimulation to sensory nerves. The technique can activate nerve pathways involved in movement, potentially reversing motor neuron dysfunction and improving muscle strength.

Researchers conducted a secondary analysis of data from a pilot clinical trial (NCT05430113) involving three adults with type 3 SMA who were able to walk. Participants completed 19 sessions of strength, endurance, and walking assessments.

Along with previously reported increases in distance and less fatigue in the six-minute walk test (6MWT), which measures how far a person can walk in six minutes, participants showed more consistent walking speed after four weeks of SCS.

Using a three-dimensional motion-capture system, available for two participants, the team also assessed walking patterns before and after treatment during the 6MWT.

After four weeks, both participants showed improvements in hip movement. Hip range of motion, which measures how far the hip joint moves during walking, increased by 48% in one participant and 11% in the other. Hip angular velocity, reflecting how quickly the hip moves, increased by 44% in one participant and 15% in the other, while angular acceleration, a measure of how quickly hip movement speed changes over time, increased by up to 28%.

Participants were also able to maintain more consistent walking speeds. One participant showed a 27% reduction in stride-to-stride speed variability, and both showed increases in stride velocity.

The researchers found no evidence that the improvements resulted from increased compensatory movements, such as hip circumduction, in which the leg moves outward in an arc to help advance the foot.

The findings support “the emerging evidence that SCS in SMA may not only improve walking performance but may also reduce underlying [walking] impairments,” the researchers wrote. This suggests that SCS may reduce “movement abnormalities and enhance treatment opportunities for SMA,” they said.

They proposed that SCS may improve movement by enhancing sensory inputs to motor neurons, helping restore more effective activation of hip and knee muscles. However, electrical activity was not measured during the walking assessments, so this proposed mechanism remains to be confirmed.

The study’s authors noted limitations including the small number of participants and the short duration of the intervention.

“Future long-term randomized controlled trials are needed to confirm these findings and to test whether a longer intervention period leads to a more complete and robust normalization of walking mechanics,” the scientists wrote.

The results, they said, “suggest that SCS is associated with kinematic [walking] changes consistent with reduced reliance on compensatory strategies in ambulatory SMA and restores normalized movement patterns.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.